Water Pump Part Series
Water Pump Part Series Production Flow:
Our Advantage
If you are interested, please contact us to talk about the details for water pump part series. You need to send us your drawing or sample to make mold first. Then we quote you price, if price accepted, we will open mold for you and send you sample before mass production.
Water Pump Part Series Water Pump Part Series,Aluminium Die Casting,Water Pump Mould,Die Casting Water Pump Part Ningbo Bowei Mould Metal Products Co., Ltd , http://en.bwmjyz.com
At the same time, Yunnan Province announced that it will vigorously develop biomedicine during the “Twelfth Five-Year Plan†and strive to reach a scale of hundreds of billions.
Shanghai and Beijing have also brewed their own "12th Five-Year Plan" for biomedicine. The overall goal of Shanghai is to bring the total economic value of the biomedical industry to 200 billion yuan by the end of 2012. Support 100 innovative companies with an annual output value of more than 200 million yuan to build 100 high-tech products with sales exceeding 100 million yuan; and Beijing strives to increase the size of the bio-pharmaceutical industry from less than 40 billion yuan in the next three years. To 100 billion yuan.
In the second half of 2010, the development momentum of the Chinese biopharmaceutical industry was like a new fire, and it was quite an embarrassment.
The ignition of the flames was the "Decision of the State Council on Accelerating the Cultivation and Development of Strategic Emerging Industries" on October 18. At this stage, we will focus on cultivating and developing seven emerging industries such as energy conservation and environmental protection, a new generation of information technology, and biology. By 2015, the value-added of strategic emerging industries will account for about 8% of the gross domestic product.
It is no doubt that biomedicine is the sunrise industry in the next 10 years. The director of the China Center for the Transformation of Pharmaceutical Science and Technology Achievement, Lou Guozhong, predicts that in 2013 China's pharmaceutical market will become the world's third largest pharmaceutical market; by 2020 China's bio-pharmaceutical industry will reach a scale of 400 billion yuan, surpassing Japan and Europe to become the world's second largest pharmaceutical market. . China’s position in the global biopharmaceutical industry is increasing.
Multi-benefits policy is about to be launched The relevant experts pointed out that the "2010-2015 Biomedical Industry Revitalization Plan" is in full swing and is expected to be introduced before the end of the year. At the same time, a number of supporting policies will be centered on the introduction of the “Twelfth Five-Year Plan†and are expected to be launched in advance.
China's biomedical industry is entering a policy benefit period. According to Luan Guozhong, "From the macro implementation of the new medical reform policy, the extended version of the basic medicine, the new version of the GMP (Pharmaceutical Production Management Standards), the 863 Plan of the biological medicine, and the creation of a major new drug technology project, to the "Special Major Infectious Diseases" of the industry. The "Drug Registration Regulations," "New Measures for Medical Devices," and "689 New Technology Standards for Chinese Medicine Injections" and other policies, including local biomedical support policies, are expected to be introduced during the year. "These favorable policies have not only come too fast." , and it will focus on reconstructing the Chinese biopharmaceutical industry chain."
Zhong Qian, director of the China Pharmaceutical Industry Confidence Center, told the Shanghai Securities News that the “12th Five-Year Plan†of biomedicine will propose nine key projects, the first of which is the development of biomedicine to promote the upgrading of the traditional pharmaceutical industry and grant financial support. "In order to promote the industrial upgrading of the pharmaceutical industry, supporting policies will soon come out."
The new GMP (Pharmaceutical Industry Pharmacy Standard) is also one of the most closely watched pending policies. According to Yu Mingde, president of the China Pharmaceutical Enterprise Management Association, the upgrading of the drug quality assurance system is an important part of the overall upgrading of the pharmaceutical industry. It is also a basis for determining the safety and efficacy of drugs. "The revised version of GMP has already passed and is going through procedures. It will also be expected to be introduced in the near future."
Zhong Qian told reporters that the new version of GMP has a three-year transitional period. Overdue enterprises that failed to meet the standard were ordered to rectify or stop production. "GMP's software requirements for pharmaceutical manufacturing companies have increased dramatically. This has always been a weakness of China's pharmaceutical companies."
In addition to pharmaceutical standards, new drug product standards are also being upgraded. "In this five-year plan, the state will have a series of concrete actions to promote the improvement of drug product standards. These include Chinese medicine, Chinese medicine injections, biochemical injections, including control of raw materials and pharmaceutical impurities and solvent residues, and some new ones. Test items and methods. These are relatively large changes, may also introduce some new modern Chinese medicine product standards." Yu Mingde said.
At the same time, in order to enhance the ability to innovate, the Shanghai Securities News reporter was exclusively informed that the "12th Five-Year Plan" for the creation of major new drugs has also been promulgated in conjunction with the "12th Five-Year Plan" for biomedicine. The scale of financial support for the development of major innovative drugs will be expanded from 6.6 billion in the “Eleventh Five-Year Plan†period to 10.5 billion. The first batch of 300 winning projects is also expected to be announced during the year. The scale of support funds for individual drug development projects ranges from 100 to 10 million, and the scale of support for technology development platforms ranges from 1,000 to 60 million. These policies will “enchant†enterprises to increase R&D. In addition, according to the Deputy Director of Biomedicine Division of Shanghai Science and Technology Commission, Zheng Zhongmin, the reporter said that at present, the Legislative Affairs Office of the State Council is implementing the Measures for the Administration of Drug Registration and the New Administrative Measures for Medical Devices. Consultation to clarify the "industrialization orientation between scientific research institutions and enterprises."
The double temptations of high growth rates and high profit margins are indicated by Ming De. The National Twelfth Five-Year Plan has identified the priorities for the development of biomedicine, including genetic drugs, protein drugs, monoclonal antibody clones, therapeutic vaccines, and small molecule chemical drugs. And so on, these policies will actively promote the rapid development of China's bio-pharmaceuticals, and the bio-pharmaceutical industry is expected.
Guo Fanli, a research fellow of China Investment Advisor Pharmaceutical Industry, pointed out to reporters that the Chinese biopharmaceutical industry will maintain rapid growth in the future. "In 2009, the total sales revenue of China's biopharmaceutical industry reached 75.3 billion yuan, and this growth rate has made it one of the fastest growing areas in the pharmaceutical industry. At the same time, the profit growth rate of the biopharmaceutical industry is as high as 70%. The growth rate and high profit growth rate have also made the biopharmaceutical industry one of the most prominent targets in emerging industries."
Stimulated by policy guidance and high profits and high growth rates, a group of traditional Chinese pharmaceutical companies will also transform themselves into biomedical companies.
A listed pharmaceutical company CEO, who produces Chinese and Western pharmaceutical raw materials and pharmaceutical intermediates, told reporters that the company plans to use a period of 5 to 10 years to completely transform itself into a bio-pharmaceutical company, and has invested huge funds in research and development. He disclosed that "The R&D investment for the refined JE vaccine project will reach 80 million yuan and will be sold within 2 years; the total investment in the humanized anti-tumor factor monoclonal antibody project is 1 billion yuan."
The investment in biomedical projects has also brought real and sustainable profit growth to traditional pharmaceutical companies. According to Zhong Shan, deputy general manager of Health Element, the cephalosporin antibiotic intermediate 7aca currently produced in Jiaozuo, Henan Province, has achieved great success. This project has become the company’s most important and fastest growing source of profit. “We use soybeans and corn to produce 7aca, which is environmentally friendly and current production capacity is expanding.â€
The relevant person of Shenzhen Mindray Biomedical Electronics Co., Ltd., a company successfully listed on the New York Stock Exchange of the United States, put forward to reporters that in the field of bio-electronic medical devices, there are industrial support, technical standards are missing, and foreign companies are crowded out. Pressure problem. He told reporters that it is foreseeable that the concentration of the biopharmaceutical industry will be higher and higher within 10 years. For large leading enterprises, the government should provide better services and build a public R&D platform to enhance their competitiveness.
Right now, government departments everywhere have realized the significance of the biomedical industry for local economic development, and have already introduced tilting policies.
According to relevant sources from the Shenzhen Bureau of Industry, Trade and Information, the city will give a total of over 10 billion in development funds to the emerging industries such as the Internet, new energy, and bio-medicine. "Soon, the first batch of 35 biomedical support projects will be approved."
1) Aluminum Die Casting part/water pump part series
2) Water pump part series conforms to ISO9001 standard
3) Clients' drawings and samples are highly followed.
4) Machining all sorts of styles, according to customers' requirements
5) Strong R&D center design system and strict inspection processes to ensure the water pump part series quality.
6) Aluminum Die Casting suitable for communications, auto parts, Lamp Part Series , water pump part series, Power Tool Series, radiator part series, anti-static flooring products and Other Series Products.
Drawings→ mould making →raw casting → sandblasting →rough machining or finish machining →surface treatment →product check→ packing →delivery strict
(1) Ten years of experience in manufacturing and exporting water pump part series.
(2) OEM and custom-made service for water pump part series.
(3) All kinds of castings can be manufactured according to drawing, sample or specific industry standard.
(4) Strong engineering team makes high quality
(5) The coordinated service (casting, machining and surface treatment) make lower price possible.
(6) Advanced-level equipments.
(7) Full material testing process and quality control system.
(8) water pump part series quality warranty and on time delivery.
Bio-pharmaceutical "12th Five-Year" supporting policy will come out
On October 25th, it was learned from the 14th Beijing International Biopharmaceutical Industry Development Forum that three billion yuan biopharmaceutical projects were under construction in this city. On the same day, China's largest pharmaceutical company, China National Pharmaceutical Group (hereinafter referred to as "China National Pharmaceutical Group"), announced that its six biological products, including its subsidiaries, Lanzhou, Wuhan, and Changchun, etc., have already been listed on the market.